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between lower thresholds for glycated hemoglo-
bin (as well as albuminuria and possibly other 
variables of interest) and adverse cardiovascular 
events were beyond the scope of our study, we 
agree that such investigations would be valuable 
and should be pursued in future studies.
In response to Magliano et al.: we agree that 
the proportion of deaths due to cardiovascular 
disease in our study is likely to be an underesti-
mation and that cardiovascular disease probably 
contributed to a fair share of the deaths catego-
rized as having diabetes as the underlying cause. 
However, because many of the deaths due to dia-
betes had multiple or unspecified complications 
(including cardiovascular disease), and further-
more, because we were not able to validate the 
final chain of events leading to death from the 
data in the register, we used a conservative ap-
proach.
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Mutations in NPC1L1 and Coronary Heart Disease
To the Editor: The Myocardial Infarction Ge-
netics Consortium Investigators (Nov. 27 issue)1 
reported an association between reduced fre-
quency of coronary artery disease and modestly 
lower levels of total cholesterol and low-density 
lipoprotein (LDL) cholesterol in carriers of inac-
tivating variants of NPC1L1 as compared with 
noncarriers. In the Geisinger MyCode cohort, we 
found seven heterozygous carriers of an inacti-
vating variant in NPC1L1 (R406X) in persons of 
European ancestry. Using a validated definition 
for coronary artery disease from the database of 
Genotypes and Phenotypes (dbGaP), we found 
no carrier of an inactivating variant of NPC1L1 
with coronary artery disease as compared with 
1001 cases of disease in 15,886 noncarriers. In 
persons for whom data on lipid levels were avail-
able before or without lipid-lowering therapy, 
there was no significant difference in mean 
plasma levels of LDL cholesterol between NPC1L1 
inactivating carriers and noncarriers (126 mg per 
deciliter vs. 125 mg per deciliter), and mean total 
cholesterol was lower in NPC1L1 inactivating car-
riers than in noncarriers (206 mg per deciliter vs. 
210 mg per deciliter). Our data are consistent 
with the suggestion of the Consortium that the 
modest change in plasma lipid levels alone does 
not explain the apparent protective effect of 
the NPC1L1 stop variants against coronary artery 
disease.
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To the Editor: The Myocardial Infarction Genet-
ics Consortium Investigators tested the association 
between inactivating mutations in NPC1L1 and 
the risk of coronary heart disease. Heterozygous 
carriers of NPC1L1 inactivating mutations had a 
mean LDL cholesterol level that was only 12 mg 
per deciliter lower than in noncarriers, but result-
ed in a dramatic relative risk reduction of 53%. 
This finding validates the concept that lifelong 
LDL cholesterol reduction has a greater impact 
on risk1 than pharmacologic interventions, such 
as statin therapy, initiated later in life.2
We have previously hypothesized that increased 
dietary sterol (cholesterol and xenosterol) absorp-
tion via NPC1L1 is associated with increased 
cardiovascular risk.3,4 We further posit that there 
are sterol species in our diets (such as oxysterols, 
oxyphytosterols, etc.) that may be mechanisti-
cally linked to atherosclerosis development. We 
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recommend plant sterol levels be determined in 
this study population to further assess cardio-
vascular risk in relation to non-cholesterol sterol 
absorption via NPC1L1. More attention should 
now be focused on these pathways and concepts 
to prevent atherosclerotic disease. The study by 
Kathiresan and colleagues suggests that dietary 
sterol exposure deserves increased scrutiny and 
investigation.
Oliver Weingärtner, M.D.
European Medical School Oldenburg-Groningen 
Oldenburg, Germany 
oweingartner@aol.com
Dieter Lütjohann, Ph.D.
University Clinics Bonn 
Bonn, Germany
Shailendra B. Patel, M.D., Ph.D.
Clement J. Zablocki Veterans Affairs Medical Center 
Milwaukee, WI
Dr. Weingärtner reports receiving lecture fees and consulting 
fees from Merck; Dr. Lütjohann, grants from Unilever; and Dr. 
Patel, consulting fees from Retrophin and Merck. No other po-
tential conflict of interest relevant to this letter was reported.
1. Ference BA, Yoo W, Alesh I, et al. Effect of long-term expo-
sure to lower low-density lipoprotein cholesterol beginning 
early in life on the risk of coronary heart disease: a Mendelian 
randomization analysis. J Am Coll Cardiol 2012;60:2631-9.
2. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of 
cholesterol-lowering treatment: prospective meta-analysis of 
data from 90,056 participants in 14 randomised trials of statins. 
Lancet 2005;366:1267-78. [Errata, Lancet 2005;366:1358, 2008; 
371:2084.]
3. Weingärtner O, Lütjohann D, Ji S, et al. Vascular effects of 
diet supplementation with plant sterols. J Am Coll Cardiol 2008; 
51:1553-61.
4. Patel SB, Salen G. Sitosterolemia: xenophobia for the body: 
In: Vissers MN, Kastelein JJP, Stroes ES, eds. Evidence-based 
management of lipid disorders. Harley, United Kingdom: tfm 
Publishing, 2010:217-30.
DOI: 10.1056/NEJMc1500124
To the Editor: The findings reported by the Myo-
cardial Infarction Genetics Consortium Investiga-
tors are very much in agreement with the obser-
vation that common variants within ABCG5/G8, 
which are associated with increased cholesterol 
absorption and LDL cholesterol, are correlated 
with higher cardiovascular risk.1,2 Although the 
beneficial effect of inactivating mutations within 
the NPC1L1 gene with regard to cardiovascular 
outcomes is plausible, the effect size seems rela-
tively large. The authors offered several possible 
explanations for the higher than expected effect 
size including the suggestion that lower concen-
trations of plant sterols may contribute to reduc-
tion of cardiovascular risk. Stender et al. have 
demonstrated in two Danish cohorts that the 
increase in cardiovascular risk associated with 
variants in ABCG5/G8, which are also associated 
with increased plant sterols, can be entirely ex-
plained by the increase in LDL cholesterol.3 More-
over, alterations of plant sterols were not associ-
ated with cardiovascular risk in patients without 
sitosterolemia.4 Finally, patients with sitosterol-
emia do not necessarily have normal LDL choles-
terol.5 Therefore, sample size issues rather than 
low plant sterols may explain the relatively large 
effect size.
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To the Editor: The Myocardial Infarction Genet-
ics Consortium Investigators assess the protective 
role of inactivating mutations in NPC1L1 on cor-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on March 16, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 372;9 nejm.org february 26, 2015 883
onary heart disease, finding a greater benefit 
than expected on the basis of the reduction in 
LDL cholesterol levels. Another contributing fac-
tor may be the involvement of NPC1L1 and its 
inhibitor ezetimibe on insulin resistance path-
ways. Ezetimibe has been reported to have an 
inhibitory effect on hepatic synthesis of LDL and 
progression to steatosis, as well as on the in-
duced augmentation of adiponectin production.1 
However, studies have also demonstrated an ac-
tion of ezetimibe in the reduction of blood insu-
lin and HbA1C levels.2 Possible mechanisms in-
clude an increase in glucagon-like peptide-1 
activity and in pancreatic beta cell mass, which 
have been observed in animal models.3 This is 
consistent with the finding of increased insulin 
sensitivity in NPC1L1 knock out mice, or in mice 
treated with ezetimibe, when exposed to a dia-
betogenic diet.4 The role of these pathways and 
NPC1L1 mutations on glucose metabolism merits 
further in vivo investigation.
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The Concept of Risk in Comparative Effectiveness Research
To the Editor: Lantos and Spertus (Nov. 27 is-
sue)1 highlight a problem with the latest draft 
of the Office for Human Research Protections 
(OHRP) policy: the assumption that participation 
in a study inherently poses a risk, regardless of 
the treatment provided.2 The results of two large 
systematic reviews refute this assumption.3,4
Vist et al.3 assessed trial participation by com-
paring similar patients receiving similar treat-
ment inside and outside trials. They concluded 
that trial participants fared no worse or no better 
than their nontrial counterparts. 
Fernandes et al.4 took a broader approach and 
included studies that provided the same treat-
ment inside and outside the trial and studies in 
which a treatment was provided within the trial 
that was unavailable outside the trial. Regardless 
of the study type, there was no evidence to sug-
gest that trial participants were worse off than 
nonparticipants. In fact, within one subgroup, 
trial participants even fared better than nonpar-
ticipants, possibly because they were given a 
more effective treatment. The OHRP should re-
consider its overgeneralized policy, which mis-
informs patients by portraying their doctor’s 
preference as consistently safer than any study 
treatment.
Natasha Fernandes, M.Sc.
University of Ottawa 
Ottawa, ON, Canada 
nfern008@uottawa.ca
Gunn Vist, Ph.D.
Norwegian Knowledge Center for Health Services 
Oslo, Norway
Dianne Bryant, Ph.D.
University of Western Ontario 
London, ON, Canada
No potential conflict of interest relevant to this letter was re-
ported.
1. Lantos JD, Spertus JA. The concept of risk in comparative-
effectiveness research. N Engl J Med 2014;371:2129-30.
2. Department of Health and Human Services. Draft guidance 
on disclosing reasonably foreseeable risks in research evaluating 
standards of care. Fed Regist 2014;79(206):63629-34 (http://
www.gpo.gov/fdsys/pkg/FR-2014-10-24/pdf/2014-25318.pdf).
3. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. 
Outcomes of patients who participate in randomized controlled 
trials compared to similar patients receiving similar interventions 
who do not participate. Cochrane Database Syst Rev 2008;3: 
MR000009.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on March 16, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
